Analysis of Fas and Fas ligand expression and function in lung cancer cell lines

European Journal of Cancer

Volumn 36, Issue 5, 2000, Pages 656-663

  Kawasaki, M ^a   Kuwano, K ^a   Nakanishi, Y ^a   Hagimoto, N ^a   Takayama, K ^a   Pei, X H ^a   Maeyama, T ^a   Yoshimi, M ^a   Hara, N ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cisplatin; Fas; Fas ligand; Lung cancer

Indexed keywords

ANTIBODY; CISPLATIN; FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CISPLATIN; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 0034100464     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00332-9     Document Type: Article

References (36)

1. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
2. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
3. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:1995;438-441.
4. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R.C. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
5. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
6. Hahne M., Rimoldi D., Schroter M.et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand. implications for tumor immune escape Science. 274:1996;1363-1366.
7. Strand S., Hofmann W.J., Hug H.et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1996;1361-1366.
8. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack. Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J. Exp. Med. 184:1996;1075-1082.
9. Niehans G.A., Brunner T., Frizelle S.P.et al. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007-1012.
10. Walker P.R., Saas P., Dietrich P.Y. Role of Fas ligand (CD95L) in immune escape. the tumor cell strikes back J. Immunol. 158:1997;4521-4524.
11. Leithauser F., Dhein J., Mechtersheimer G.et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69:1993;415-429.
12. Moller P., Koretz K., Leithauser F.et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer. 57:1994;371-377.
13. Hellquist H.B., Olejnicka B., Jadner M., Andersson T., Sederholm C. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced. a preliminary report Br. J. Cancer. 76:1997;175-179.
14. Nambu Y., Hughes S.J., Rehemtulla A., Hamstra D., Orringer M.B., Beer D.G. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J. Clin. Invest. 101:1998;1102-1110.
15. Friesen C., Herr I., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:1996;574-577.
16. Muller M., Strand S., Hug H.et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:1997;403-413.
17. Villunger A., Egle A., Kos M.et al. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57:1997;3331-3334.
18. Eischen C.M., Kottke T.J., Martins L.M.et al. Comparison of apoptosis in wild-type and Fas-resistant cells. chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions Blood. 90:1997;935-943.
19. Koomagi R., Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int. J. Cancer. 84:1999;239-243.
20. Ruckdeschel J.C., Finkelstein D.M., Ettinger D.S.et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J. Clin. Oncol. 4:1986;14-22.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival. application to proliferation and cytotoxicity assays J. Immunol. Methods. 65:1983;55-63.
22. Hagimoto N., Kuwano K., Kawasaki M.et al. Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am. J. Respir. Cell. Mol. Biol. 21:1999;436-445.
23. Zhang C., Ao Z., Seth A., Schlossman S.F. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J. Immunol. 157:1996;3980-3987.
24. Higaki K., Yano H., Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am. J. Pathol. 149:1996;429-437.
25. Owen-Schaub L.B., Radinsky R., Kruzel E., Berry K., Yonehara S. Anti-Fas on nonhematopoietic tumors. levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness Cancer Res. 54:1994;1580-1586.
26. Weller M., Frei K., Groscurth P., Krammer P.H., Yonekawa Y., Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94:1994;954-964.
27. Zeytun A., Hassuneh M., Nagarkatti M., Nagarkatti P.S. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes. a lethal two-way street Blood. 90:1997;1952-1959.
28. Villunger A., Egle A., Marschitz I.et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells. a potential mechanism of tumor-induced suppression of immune surveillance Blood. 90:1997;12-20.
29. Ungefroren H., Voss M., Jansen M.et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 58:1998;1741-1749.
30. Rathmell J.C., Townsend S.E., Xu J.C., Flavell R.A., Goodnow C.C. Expansion or elimination of B cells in vivo. dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor Cell. 87:1996;319-329.
31. Thilenius A.R., Braun K., Russell J.H. Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Eur. J. Immunol. 27:1997;1108-1114.
32. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:1997;2045-2050.
33. Sen S., D'Incalci M. Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett. 307:1992;122-127.
34. Mesner P.W. Jr., Budihardjo I.I., Kaufmann S.H. Chemotherapy-induced apoptosis. Adv. Pharmacol. 41:1997;461-499.
35. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K.M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57:1997;3823-3829.
36. Kataoka T., Schroter M., Hahne M., Schneider P.et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J. Immunol. 61:1998;3936-3942.